BCL2L11 and plasma cell myeloma: Moreover, it was reported that HDACi could inhibit the expression of MCL1 and BCL-XL as well as increase the expression of BIM in a variety of tumor cells [18–20], which may be associated with the synergistical anti-myeloma effect of chidamide and venetoclax.